Focused On-demand Library for Dehydrogenase/reductase SDR family member 4-like 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q6PKH6

UPID:

DR4L2_HUMAN

Alternative names:

Short chain dehydrogenase/reductase family 25C member 3

Alternative UPACC:

Q6PKH6; H0YN69; Q3YLD4

Background:

Dehydrogenase/reductase SDR family member 4-like 2, also known as Short chain dehydrogenase/reductase family 25C member 3, is classified as a probable oxidoreductase. This protein plays a pivotal role in the metabolic processes, catalyzing the oxidation-reduction reactions that are crucial for cellular energy production and detoxification.

Therapeutic significance:

Understanding the role of Dehydrogenase/reductase SDR family member 4-like 2 could open doors to potential therapeutic strategies. Its involvement in key biochemical pathways highlights its potential as a target for drug discovery, aiming to modulate its activity for therapeutic benefits.